EP 96. Sensor based gait analysis application for apomorphine titration

• Published in: Clinical neurophysiology 2016-09, Vol.127 (9), p.e283-e283
• Main Authors: Marxreiter, F, Gassner, H, Barth, J, Thun, C, Volc, D, Schlachetzki, J, Winkler, J, Eskofier, B, Klucken, J
• Format: Article
• Language: English
• Subjects: Neurology
• ISSN: 1388-2457; 1872-8952
• DOI: 10.1016/j.clinph.2016.05.143

Parkinson’s disease (PD) is a prototypical movement disorder and gait impairment like small steps and shuffling are main characteristics of the disease. However, the assessment of gait is underrepresented in the UPDRS motor score. The sensor-based gait analysis system eGaIT (embedded gait analysis using IT) offers an objective way to quantify gait signatures in PD patients. Spatio-temporal gait parameters and instrumented scores of gait impairment in PD can be obtained by eGaIT in crosssectional multicenter study designs. However, the assessment of intraindividual changes in gait is a major need for clinical care. The goal of the present study was to individualize instrumented gait parameters in a typical treatment paradigm in PD. To evaluate if intraindividual gait alterations upon dopaminergic treatment can be assessed, gait analysis was performed during the fast titration scheme for subcutaneous apomorphine treatment. We were able to identify stride speed, step length, gait velocity, max toe off as features of gait responsive to apomorphine treatment. Moreover, we show that intraindividual treatment effects on gait can be assessed by parameters obtained from a 10meter walk and that improvement of gait parameters correlates with an instrumented gait score that correlates to the UPDRS motor score. Therefore, instrumented gait analysis can provide a complementary measure of treatment efficacy.